Danifexor is the agonist for farnesoid X receptor.

DA-302168S is an orally active and selective agonist targeting the GLP-1R, with EC50 value of 1.32 nM. DA-302168S stimulates insulin secretion and shows hypoglycemic effects. DA-302168S decreases food intake. DA-302168S mainly activates GLP-1R of monkeys and humans, and exhibits little excitatory effect on GLP-1R of rats, mice, and dogs. DA-302168S can be used for type 2 diabetes and obesity study.

Cytogenin (Antibiotic MI 43-37F11) is an orally active antineoplastic antibiotic. Cytogenin regulates the inflammatory cytokine, reduces the levels of iNOS, NO and IL-6 in mouse macrophages, and exhibits antidiabetic efficacy in mice. Cytogenin inhibits growth of Ehrlich ascites tumor in mouse model.

Cy3-PEG-FA (MW 2000) is a fluorescent folate-PEG derivative with excitation/emission wavelengths of ~550 nm/~570 nm. Cy3-PEG-FA (MW 2000) can be readily traced by its intense red fluorescent signal. Cy3-PEG-FA (MW 2000) can be used for cell imaging, folate receptor targeting and detection.

CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease.

CTT2274 is a prodrug of MMAE analog. SPA107 inhibits the polymerization of tubulin, exhibits antimitotic activity (IC50 of 0.5 nM) and cytotoxicity in p53 mutated MCF-7 cell with IC50 of 0.5 nM.

CQ1373 is a potent RET inhibitor, demonstrating cellular potency with IC50 values of 13.0, 25.7 and 28.4 nM against BaF3 cells expressing CCDC6-RET, CCDC6-RET-G810C and CCDC6-RET-G810R, respectively. CQ1373 exhibits good selectivity toward wild-type RET and solvent front mutants G810C/R with IC50 values of 4.2, 7.1 and 32.4 nM, respectively. CQ1373 inhibits RET phosphorylation and downstream signaling through SHC. CQ1373 induces Apoptosis and cell cycle arrest in BaF3 cells. CQ1373 exhibits anti-tumor efficacy and can be used for cancer research.

CPW-86-363 is a novel broad-spectrum cephalosporin with antibacterial activity.

CP-865569 is a CCR1 antagonist. CP-865569 can be used in the research of inflammatory diseases and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

CP-506 (compound 26) mesylate is an anticancer compound and a substrate for nitroreductase and CYP oxidoreductases. CP-506 has anticancer activity.

CP-31398 can stabilize the active conformation of p53 and promote p53 activity in cancer cells with either mutant or wild-type p53. In addition, CP-31398 can upregulate p53 target genes, such as p21WAF1/Cip1 and KILLER/DR5. CP-31398 exerts an inhibitory effect on tumor growth.

Corynecin III is a Chloramphenicol-like antibiotic, which is found in Corynebacterium. Corynecin III inhibits the growth of Gram-positive and Gram-negative bacteria with MIC values of 2.6-83 μg/mL.

Corynecin I is an antibiotic produced by Corynebacterium hydrocarboclastus, and its precursor (D-(-) threo-p-amino phenyl serinol-N-acetylamine) has a minimal inhibitory effect on the synthesis of Corynecin from mevalonic acid.

Conteltinib tetrahydrochloride (CT-707 tetrahydrochloride) is the tetrahydrochloride salt form of Conteltinib. Conteltinib tetrahydrochloride is the inhibitor for FAK (IC50=1.6 nM), ALK, and Pyk2. Conteltinib tetrahydrochloride exhibits a synergistic anti-tumor efficacy with Cabozantinib.

C-MS023 is a photo-activatable MS023 based cereblon ligand and a linker used in PROTAC technology. Thalidomide-piperidine-C2-piperazine-Boc can be used for synthesis of PROTACs.

CM-728 is a oxazepine-naphthoquinone that has cytotoxic and bactericidal effect. CM-728 is a human peroxiredoxin-1 inhibitor. CM-728 is an oxidative stressor that affects mitochondrial function.

CM112 is a selective protein arginine methyltransferase 1 (PRMT1) degrader by tethering hydrophobic tag, adamantane, to MS023 with a 5-PEG linker. CM112 induces the degradation of PRMT1 in various solid cancer cell lines. CM112 can also target the nonenzymatic function of PRMT1 by downregulating the stability of the orphan receptor TR3. CM112 is promising for research of cancers.

CLPP-2068 is the orally active activator for human caseinolytic protease P (HsClpP) with an EC50 of 50.4 nM. CLPP-2068 exhibits anti-proliferative efficacy in OCI-LY10 cancer cell with an IC50 of 5.2 nM. CLPP-2068 decreases mitochondrial membrane potential, increases mitochondrial ROS levels, and induces mitochondrial dysfunction. CLPP-2068 arrests the cell cycle at G1 phase, and induces apoptosis in cell OCI-LY10. CLPP-2068 exhibits antitumor activity in mouse xenograft models.

Clotizolam is a thienobenzodiazepine derivative that has antagonistic activity against platelet-activating factor (PAF). Clotizolam possesses sedative, anxiolytic, anticonvulsant,and muscle relaxant effects.

CL2A-FL118 is a drug-linker for synthesis of ADC molecule Sac-CL2A-FL118.

CJZ3 is an reversible inhibitor for P-glycoprotein (P-gp), that accumulates the drug (Rh123) in cells, and improve the permeability of the blood-brain barrier (BBB).

CIL-102, an apoptosis inducer, is a MMP-2/MMP-9 inhibitor that decreases MMP-2/MMP-9 protein expression and mRNA levels. CIL-102 displays an anti-cancer activity.

Cholesterol β-D-glucoside (Cholesteryl glucoside) is a heat shock transcription factor 1 (HSF1) activator. Cholesterol β-D-glucoside induces HSP70 in fibroblast cells.

Chloranocryl (Dicryl) is a herbicide, and is effective when applied at the early growth stage. Chloranocryl has high activity against Brassica rapa and low activity against rice.

CHL2310 is the inhibitor for CYP46A1 with an IC50 of 0.11 nM, and a Kd of 0.37 nM. CHL2310 can cross blood-brain barrier. CHL2310 can be used as a PET imaging agent, when labeled with radioactive 18F.

ChEMBL22003 is a potential phase separation modulator of ARV7 that can bind to the ARV7 binding sites. ChEMBL22003 has potential for use in the research of prostate cancer.

CGS 24592 is an orally active, selective and potent neutral endopeptidase 24.11 (NEP) inhibitor with an IC50 value of 1.6 nmol/L. CGS 24592 reduces the degradation of atrial natriuretic peptide (ANP), increases the concentration of ANP in the plasma, and reduces blood pressure. CGS 24592 is promising for research of cardiovascular disease, such as hypertension and congestive heart failure.

Cetagliptin is an orally active inhibitor for dipeptidyl peptidase 4 (DPP-4) and CYP2D6 (IC50 of 6 µM). Cetagliptin is a substrate for P-glycoprotein. Cetagliptin reduces the GLP-1 degradation, maintains the level of postprandial blood sugar, and can be used in type 2 diabetes mellitus research.

Cefoxazole is a β-lactam antibiotic containing an isoxazole moiety and exhibits antibacterial activity. Cefoxazole can be used in studies related to infectious diseases.

CDD-1431 is a low-nanomolar selective kinase inhibitors of BMPR2, with Kiapp value of 20.6 nM. CDD-1431 suppresses BRE-reporter activity, with an IC50 of 4.87 μM. BMP controls cellular processes across many tissue types, including the kidney, skeletal muscle, heart, and reproductive organs. BMP induces ectopic bone formation.